~ Buy the DUOBRII (halobetasol propionate; tazarotene) Drug Profile, 2024 PDF Report in the Report Store ~

Drug Price Trends for duobrii

Average Pharmacy Cost for duobrii

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
DUOBRII 0.01%-0.045% LOTION	00187-0653-01	9.92642	GM	2024-12-18
DUOBRII 0.01%-0.045% LOTION	00187-0653-01	9.91729	GM	2024-11-20
DUOBRII 0.01%-0.045% LOTION	00187-0653-01	9.92308	GM	2024-10-23
DUOBRII 0.01%-0.045% LOTION	00187-0653-01	9.92462	GM	2024-09-18

Duobrii Market Analysis and Financial Projection

Market Analysis and Price Projections for Duobrii

Introduction to Duobrii

Duobrii, a topical lotion formulated with halobetasol propionate and tazarotene, is a significant advancement in the treatment of moderate to severe plaque psoriasis. Developed by Ortho Dermatologics, a division of Bausch Health Companies, Duobrii is the first and only topical treatment that combines a potent corticosteroid (halobetasol propionate) with a retinoid (tazarotene) in a single formulation[1].

Market Growth and Drivers

The plaque psoriasis market, in which Duobrii is a key player, is expected to exhibit robust growth. Here are some key drivers:

• Biologic Therapies and Customized Treatments: The market is driven by the increasing adoption of novel biological treatments and customized treatment approaches. Biologics, in particular, are revolutionizing the treatment landscape by providing more targeted and effective options[1].
• Increasing Prevalence: The total diagnosed prevalence of plaque psoriasis is steadily increasing across major markets, contributing to the growth of the PsO market[3].
• Pipeline Agents: The launch of new pipeline agents such as SAR44156, JNJ-2113, sonelokimab, DC-806, orismilast, Piclidenoson, and TAK-279 is expected to further boost the market[3].

Market Size and Projections

By 2030, the global plaque psoriasis market is projected to reach $31.7 billion, representing a compound annual growth rate (CAGR) of 10.6% over the 10-year forecast period. This growth is significantly higher than other therapeutic areas, indicating a strong demand for effective treatments like Duobrii[3].

Competitive Landscape

Duobrii operates in a competitive market with several existing and pipeline treatments. Here are some key aspects of the competitive landscape:

• In-Market Drugs: Duobrii competes with other topical and systemic treatments. Its unique combination of a corticosteroid and a retinoid sets it apart, offering a dual mechanism of action that effectively treats plaque psoriasis[1].
• Pipeline Drugs: The launch of new pipeline agents will increase competition but also expand treatment options for patients, potentially driving market growth[3].

Pricing and Cost Considerations

The pricing of Duobrii is a critical factor in its market performance:

• Current Pricing: The cost for Duobrii (0.01%-0.045%) topical lotion is around $1,103 for a supply of 100 grams, depending on the pharmacy. This price is for cash-paying customers and does not include insurance plans[2].
• Patient Assistance Programs: To make Duobrii more accessible, Ortho Dermatologics offers various savings programs. For example, eligible commercially insured patients can pay as little as $25 per prescription, while those without coverage may pay $65 or $75 per prescription, depending on the program[2][5].

Pharmacoeconomic Analysis

The pharmacoeconomic analysis of Duobrii highlights several key points:

• Cost-Effectiveness: The incremental cost-effectiveness ratio (ICER) for Duobrii is estimated to be around $85,670 per quality-adjusted life-year (QALY), although this can vary significantly based on the patient population and treatment setting[4].
• Comparison with Other Treatments: Duobrii is more expensive than some other topical treatments like betamethasone dipropionate and calcipotriol (BD/CAL), but its unique formulation and efficacy profile justify the higher cost in many cases[4].

Barriers to Growth

Despite the positive outlook, there are several barriers to growth in the plaque psoriasis market that could impact Duobrii:

• Patent Expirations and Biosimilars: The loss of patent protection for biologics like Stelara (ustekinumab) and Cosentyx, and the subsequent launch of their biosimilars, could reduce market share for branded drugs[3].
• Generic Launches: The launch of generic versions of apremilast in 2028 could also impact the market dynamics and pricing strategies for Duobrii[3].
• Legislative Changes: Legislation aimed at reducing drug prices, such as the Inflation Reduction Act (IRA) in the US, could influence the pricing and reimbursement landscape for Duobrii[3].

Key Takeaways

• Market Growth: The plaque psoriasis market is expected to grow significantly, driven by novel biological treatments and increasing prevalence.
• Unique Formulation: Duobrii's combination of halobetasol propionate and tazarotene offers a dual mechanism of action, making it a valuable treatment option.
• Pricing and Assistance: While Duobrii is expensive, patient assistance programs help make it more accessible.
• Pharmacoeconomic Considerations: Duobrii's cost-effectiveness varies, but it is generally more expensive than some other topical treatments.
• Barriers to Growth: Patent expirations, generic launches, and legislative changes could impact the market.

FAQs

Q: What is Duobrii used for? A: Duobrii is used for the treatment of moderate to severe plaque psoriasis in adult patients.

Q: How much does Duobrii cost? A: The cost for Duobrii (0.01%-0.045%) topical lotion is around $1,103 for a supply of 100 grams, but patient assistance programs can reduce this cost significantly.

Q: What makes Duobrii unique? A: Duobrii is the first and only topical treatment that combines a potent corticosteroid (halobetasol propionate) with a retinoid (tazarotene) in a single formulation.

Q: Are there any patient assistance programs for Duobrii? A: Yes, Ortho Dermatologics offers several savings programs that can reduce the cost of Duobrii for eligible patients.

Q: What are the potential barriers to growth for Duobrii in the market? A: Patent expirations, the launch of generic versions of other treatments, and legislative changes aimed at reducing drug prices are potential barriers.

Sources

1. Biospace: Plaque Psoriasis Market Estimated to Reach a CAGR of 8.93% During 2024-2034[1].
2. Drugs.com: Duobrii Prices, Coupons, Copay Cards & Patient Assistance[2].
3. GlobeNewswire: Plaque Psoriasis Drug Forecast and Market Analysis to 2030[3].
4. CADTH: Pharmacoeconomic Review Report for Halobetasol Propionate and Tazarotene (Duobrii)[4].
5. Duobrii.com: Savings and Resources. DUOBRII® (halobetasol propionate and tazarotene) topical lotion[5].